What's Happening?
Guided Therapeutics, Inc., based in Peachtree Corners, Georgia, has filed the results of its multicenter clinical trial with the U.S. Food and Drug Administration (FDA) for its LuViva Advanced Cervical Scan. This device is a non-invasive testing platform
designed to detect cervical cancer using patented biophotonic technology. The trial involved 480 women who were referred for biopsy due to abnormal Pap and/or HPV tests. Of the 428 women who completed the study, 99 were found to have significant cervical disease, with 32 cases undetected by the current standard of care. LuViva successfully identified 21 of these 32 cases, increasing the detection rate from 68% to 89%. The study met all primary and secondary endpoints regarding sensitivity and specificity, with no safety issues reported.
Why It's Important?
The submission of this clinical report to the FDA is a significant step for Guided Therapeutics as it seeks approval for its LuViva device. The ability to detect cervical cancer earlier than conventional methods could have a profound impact on women's health, potentially reducing the incidence of advanced cervical cancer cases. This development could also influence the medical device industry by setting a new standard for non-invasive cancer detection technologies. If approved, LuViva could provide a more effective screening tool, benefiting healthcare providers and patients by offering earlier intervention options.
What's Next?
Guided Therapeutics awaits the FDA's review of the clinical trial results. The company plans to work with its physician team to publish the study findings in a medical journal, which could further validate the device's efficacy. The outcome of the FDA's review will determine the next steps for LuViva's commercialization in the U.S. market. A positive review could lead to increased adoption of the device in clinical settings, while a negative outcome may require further trials or modifications to the device.
